Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
2(25%)
Results Posted
60%(3 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_3
2
25%
Ph phase_2
4
50%
Ph phase_1
2
25%

Phase Distribution

2

Early Stage

4

Mid Stage

2

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
2(25.0%)
Phase 2Efficacy & side effects
4(50.0%)
Phase 3Large-scale testing
2(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

2

trials recruiting

Total Trials

8

all time

Status Distribution
Active(2)
Completed(5)
Terminated(1)

Detailed Status

Completed5
Recruiting2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
2
Success Rate
83.3%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (25.0%)
Phase 24 (50.0%)
Phase 32 (25.0%)

Trials by Status

recruiting225%
completed563%
terminated113%

Recent Activity

2 active trials
Showing 5 of 8
recruitingphase_3

Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients

NCT06918002
recruitingphase_2

SBRT Plus Lenalidomide for Solitary Plasmacytoma: Phase II Trial

NCT06863584
completedphase_1

Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)

NCT00831766
completedphase_2

Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphoma

NCT00478959
completedphase_3

Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old

NCT01916252
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT06918002Phase 3

Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients

Recruiting
NCT06863584Phase 2

SBRT Plus Lenalidomide for Solitary Plasmacytoma: Phase II Trial

Recruiting
NCT00831766Phase 1

Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)

Completed
NCT00478959Phase 2

Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphoma

Completed
NCT01916252Phase 3

Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old

Completed
NCT00843310Phase 2

Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma

Terminated
NCT00540644Phase 2

Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma

Completed
NCT01062152Phase 1

Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8